tailieunhanh - Báo cáo khoa học: "Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. | Available online http content 10 1 R24 Research Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding an observational study Peter Faybik1 Andreas Bacher1 Sibylle A Kozek-Langenecker1 Heinz Steltzer1 Claus Georg Krenn1 Sandra Unger2 and Hubert Hetz1 1Medical Doctor Department of Anesthesiology and General Intensive Care Medical University of Vienna Austria 2Medical Technical Assistant Department of Anesthesiology and General Intensive Care Medical University of Vienna Austria Corresponding author Peter Faybik Received 20 Sep 2005 Revisions requested 5 Dec 2005 Revisions received 21 Dec 2005 Accepted 9 Jan 2006 Published 3 Feb 2006 Critical Care 2006 10 R24 doi cc3985 This article is online at http content 10 1 R24 2006 Faybik et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction Liver failure is associated with reduced synthesis of clotting factors consumptive coagulopathy and platelet dysfunction. The aim of the study was to evaluate the effects of liver support using a molecular adsorbent recirculating system MARS on the coagulation system in patients at high risk of bleeding. Methods We studied 61 MARS treatments in 33 patients with acute liver failure n 15 acute-on-chronic liver failure n 8 sepsis n 5 liver graft dysfunction n 3 and cholestasis n 2 . Standard coagulation tests standard thromboelastography TEG and heparinase-modified and abciximab-fab-modified TEG were performed immediately before and 30 minutes after commencement of MARS and after the end of MARS treatment. Prostaglandin I2 was administered extracorporeally to all patients 17 patients additionally received unfractioned